NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2018.
“We are pleased with our progress to date in 2018, as we continue to work to strengthen our leadership position in NASH and remain on track for the top line readout of data from our Phase 3 REGENERATE trial in the first half of 2019. Based on our review of the evolving competitive landscape, the new data released at the recent International Liver Congress in Paris and the strength of OCA’s Phase 2 and other data, we continue to believe in OCA’s significant potential in NASH,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept. “In addition, we are encouraged by the recent momentum we have seen in our Ocaliva PBC business, where our team remains focused on both education and execution given the sizeable unmet medical need for this important therapy.”
Recent Developments
In April 2018, we issued and sold 2,695,313 shares of our common stock in a registered public offering at a price to the public of $64.00 per share. Our Chief Executive Officer and certain members of our board of directors participated in the public offering at the price offered to the public and on the same terms as the other purchasers in the public offering. Concurrently with the public offering, we issued and sold, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, 1,562,500 shares of our common stock to our largest existing stockholder, Genextra S.p.A., Samsara BioCapital, L.P. and certain other purchasers at a sale price equal to the price to the public in the public offering. We received net proceeds from the public offering and concurrent private placement of approximately $261.4 million, after deducting underwriting discounts, commissions and estimated offering expenses of approximately $11.1 million.
Ocaliva® (obeticholic acid or OCA) Commercial Highlights
We recorded $35.2 million of Ocaliva net sales in the first quarter of 2018, comprised of U.S. Ocaliva net sales of $28.5 million and ex-U.S. Ocaliva net sales of $6.7 million.
Ocaliva was approved in the United States by the U.S. Food and Drug Administration (“FDA”) in May 2016 for the treatment of primary biliary cholangitis (“PBC”) in combination with ursodeoxycholic acid (“UDCA”) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. We commenced sales and marketing of Ocaliva in the United States shortly after receiving marketing approval, and Ocaliva is now available to patients primarily through a network of specialty pharmacy distributors. In February 2018, the Ocaliva label in the United States was updated to include a boxed warning and a dosing table that reinforced the existing dosing schedule in PBC patients with Child-Pugh Class B or C or decompensated cirrhosis.
Ocaliva was granted conditional approval by the European Commission in December 2016 for the treatment of PBC in combination with UDCA in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA, and we commenced our European commercial launch in January 2017. Since January 2017, Ocaliva has also received regulatory approval in several of our target markets outside Europe, including Canada and Israel. We have been working with the European Medicines Agency and other relevant regulatory authorities outside the United States since the FDA’s February 2018 Ocaliva label update to harmonize the Ocaliva label outside the United States and ensure that it sufficiently reinforces the importance of appropriate dosing in PBC patients with advanced cirrhosis.
Selected First Quarter 2018 Financial Results
Revenues
We recognized $36.0 million in total revenue in the quarter ended March 31, 2018, including $35.2 million of Ocaliva net sales and $0.8 million of licensing revenue related to the amortization of upfront payments under our license agreement with Sumitomo Dainippon Pharma Co., Ltd.
Operating Expenses
Our cost of sales was $0.3 million in the first quarter of 2018. Prior to the FDA’s approval of Ocaliva, we expensed costs related to the manufacturing and buildup of our Ocaliva commercial launch supplies. As a result, our cost of sales in the quarter ended March 31, 2018 included only packaging and labeling expenses incurred during the quarter. We expect our cost of sales to remain negligible until the previously expensed supplies of Ocaliva are sold.
Our selling, general and administrative expenses increased to $62.5 million in the quarter ended March 31, 2018, up from $61.1 million in the prior year quarter. The increase was primarily due to personnel-related costs to support our continued commercial and international Ocaliva initiatives.
Research and development expenses increased to $48.7 million in the quarter ended March 31, 2018, up from $43.8 million in the prior year quarter. The increase was primarily driven by increases in OCA research and development activities, partially offset by decreases in compensation-related and other costs.
In the quarter ended March 31, 2018, we recorded $111.4 million in total operating expenses and $97.8 million in non-GAAP adjusted operating expenses, which excludes non-cash stock-based compensation expense of $12.3 million and depreciation expense of $1.3 million. References in this press release to “non-GAAP adjusted operating expenses” mean our total operating expenses, as calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), adjusted for the effects of two non-cash items: stock-based compensation and depreciation. See “Non-GAAP Financial Measures” below. A reconciliation of non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading “Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses”.
Interest Expense
Our interest expense in the quarter ended March 31, 2018 was $7.5 million. Our interest expense is related to the $460.0 million aggregate principal amount of 3.25% Convertible Senior Notes due 2023 (the “Convertible Notes”) that we issued in July 2016.
Net Loss
During the first quarter of 2018, we reported a net loss of $81.6 million.
Cash Position
As of March 31, 2018, we had cash, cash equivalents and investment securities available for sale of approximately $326.1 million, compared to $414.9 million as of December 31, 2017. Subsequently, in April 2018, we completed a public offering and concurrent private placement of our common stock. We received net proceeds from the public offering and concurrent private placement of approximately $261.4 million, after deducting underwriting discounts, commissions and estimated offering expenses of approximately $11.1 million.
2018 Financial Guidance
Based on our first quarter results and our current outlook for the remainder of 2018, we are announcing a 2018 Ocaliva net sales guidance range of between $170 million and $185 million. In addition, we are confirming our previously announced 2018 non-GAAP adjusted operating expenses guidance range of between $390 million and $410 million. See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

